180 related articles for article (PubMed ID: 38313231)
1. Revolutionizing gastric cancer treatment: The potential of immunotherapy.
Christodoulidis G; Koumarelas KE; Kouliou MN
World J Gastroenterol; 2024 Jan; 30(4):286-289. PubMed ID: 38313231
[TBL] [Abstract][Full Text] [Related]
2. Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023).
Li YN; Xie B; Zhang Y; He MH; Xing Y; Mu DM; Wang H; Guo R
World J Gastroenterol; 2023 Oct; 29(40):5593-5617. PubMed ID: 37970478
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway.
Cheng R; Li B; Wang H; Zeng Y
Clin Transl Oncol; 2023 Nov; 25(11):3122-3138. PubMed ID: 37036597
[TBL] [Abstract][Full Text] [Related]
4. [Looking back 2018--focused on gastric cancer].
Li Z; Gao X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):1-8. PubMed ID: 30703786
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma.
Hong M; Tang K; Qian J; Deng H; Zeng M; Zheng S; Ding K; Du Y; Sun R
Crit Rev Oncog; 2018; 23(3-4):219-234. PubMed ID: 30311576
[TBL] [Abstract][Full Text] [Related]
6. Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study.
Xie T; Liu Y; Zhang Z; Zhang X; Gong J; Qi C; Li J; Shen L; Peng Z
J Immunother; 2020 May; 43(4):139-144. PubMed ID: 32134806
[TBL] [Abstract][Full Text] [Related]
7. Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects.
Hou W; Zhao Y; Zhu H
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895000
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy.
Pereira MA; Batista DAM; Ramos MFKP; Cardili L; Ribeiro RRE; Dias AR; Zilberstein B; Ribeiro U; Cecconello I; Alves VAF; Mello ES
J Surg Res; 2021 May; 261():130-138. PubMed ID: 33429221
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
10. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapeutic advances in gastric cancer.
Yoneda A; Kuroki T; Eguchi S
Surg Today; 2021 Nov; 51(11):1727-1735. PubMed ID: 33590326
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for nasopharyngeal cancer-a review.
Jain A; Chia WK; Toh HC
Chin Clin Oncol; 2016 Apr; 5(2):22. PubMed ID: 27121882
[TBL] [Abstract][Full Text] [Related]
13. Gastric cancer: a comprehensive review of current and future treatment strategies.
Sexton RE; Al Hallak MN; Diab M; Azmi AS
Cancer Metastasis Rev; 2020 Dec; 39(4):1179-1203. PubMed ID: 32894370
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of gastric cancer: Past, future perspective and challenges.
Xie J; Fu L; Jin L
Pathol Res Pract; 2021 Feb; 218():153322. PubMed ID: 33422778
[TBL] [Abstract][Full Text] [Related]
15. The current management and biomarkers of immunotherapy in advanced gastric cancer.
Chang X; Ge X; Zhang Y; Xue X
Medicine (Baltimore); 2022 May; 101(21):e29304. PubMed ID: 35623069
[TBL] [Abstract][Full Text] [Related]
16. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in gastric cancer.
Matsueda S; Graham DY
World J Gastroenterol; 2014 Feb; 20(7):1657-66. PubMed ID: 24587645
[TBL] [Abstract][Full Text] [Related]
18. Immunology and immunotherapy in gastric cancer.
Xu X; Chen J; Li W; Feng C; Liu Q; Gao W; He M
Clin Exp Med; 2023 Nov; 23(7):3189-3204. PubMed ID: 37322134
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in immune therapies for gastric cancer.
Olnes MJ; Martinson HA
Cancer Gene Ther; 2021 Sep; 28(9):924-934. PubMed ID: 33664460
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
